New U.S. Treasury rules on inversion deals are unlikely to scuttle Medtronic's pending $43 billion merger with Covidien, analysts say, but are likely to make it more complicated and expensive.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1xg2BrR
Cap comentari:
Publica un comentari a l'entrada